Clinical Advisory from NINDS
The National Institute of Neurological Disorders and Stroke (NINDS) issued a new Clinical Advisory on September 19, 2011:
Secondary Prevention of Small Subcortical Strokes Trial: NINDS Stops Treatment with Combination Antiplatelet Therapy (Clopidogrel plus Aspirin) Due to Higher Risk of Major Hemorrhage and Death (http://www.nlm.nih.gov/databases/alerts/2011_ninds_stroke.html)
NINDS has stopped the combination antiplatelet intervention in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. This was a randomized, multicenter clinical trial conducted throughout North America, Latin America and Spain, to learn about preventing a second stroke in patients who had a subcortical stroke and to learn how to prevent cognitive problems after a stroke.
[NLM Technical Bulletin, September 19, 2011]